Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin G (IgG) is used in specific cases of sinus infections, particularly for patients with underlying immune deficiencies. Scientific evidence supports the use of intravenous or subcutaneous immunoglobulin (IVIG/SCIG) therapy in individuals who have primary immunodeficiency diseases (PIDs), such as Common Variable Immunodeficiency (CVID) or X-linked Agammaglobulinemia. These patients are prone to recurrent and severe sinus infections due to their inability to produce adequate endogenous antibodies, including IgG. Multiple clinical studies and guidelines (e.g., from the American Academy of Allergy, Asthma & Immunology) recommend immunoglobulin replacement therapy to reduce the frequency and severity of infections, including chronic or recurrent sinusitis, in such populations. However, there is no evidence supporting the use of IgG for treating acute or uncomplicated sinus infections in immunocompetent individuals. For the general population, antibiotics and symptomatic management remain the standard of care, and IgG therapy is not indicated. Therefore, while the use of IgG is scientifically justified and effective for a specific subset of patients with immune deficiencies and recurrent sinusitis, it is not a recommended or evidence-based treatment for sinus infections in otherwise healthy individuals.

More about immunoglobin G
More about Sinus Infection

Other ingredients used for Sinus Infection

Other health conditions supported by immunoglobin G

Products containing immunoglobin G